CNS and Neuromuscular
In July of 2021, Ionis entered into a worldwide license and collaboration agreement for tissue-targeted delivery of oligonucleotide therapeutics using Bicycles with high affinity to the transferrin receptor (TfR1). This collaboration was a result of Bicycles’ demonstrated ability to selectively deliver a variety of payloads into solid tumors when targeted to specific tumor antigens. Ionis and Bicycle will collaborate to develop a pipeline of oligonucleotide therapeutic product candidates. Bicycle is eligible to receive development, regulatory and commercial milestone payments and royalties for each program developed under the collaboration.